Business Standard

Dr Lal Pathlabs Ltd News

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside
Updated On : 05 Jul 2024 | 11:15 AM IST

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill

Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill
Updated On : 29 May 2024 | 8:32 PM IST
Updated On : 10 May 2024 | 7:16 PM IST

Dr. Lal PathLabs Q4 results: Net profit rises 49% on healthy testing demand

The company's consolidated net profit jumped 49% year-on-year to Rs 84.5 crore ($10.1 million) in the fourth quarter

Dr. Lal PathLabs Q4 results: Net profit rises 49% on healthy testing demand
Updated On : 10 May 2024 | 3:44 PM IST

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%

Dr Lal PathLabs reported an increase in its network of Patient Service Centres (PSCs) and Pick-Up Centres (PUPs) across the country. It also reported a 2 per cent rise in revenue from Tier 3 cities

Dr Lal PathLabs Q3 results: Profit jumps 53.3%, revenue up by 10.1%
Updated On : 01 Feb 2024 | 10:06 PM IST

Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%

The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu

Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%
Updated On : 01 Feb 2024 | 3:38 PM IST